Effect of various MGO components on plasma lipid contents in hyperlipidemic rats.

The placebo group (A) was administered 1 ml carrier alone, whereas, the Triton WR-1339 group (B) was administered 1 ml carrier and one h later 1 ml of Triton WR-1339 (200 mg/kg of body weight). The rats in group (C) were treated with various MGO components and one h later were treated with Triton WR-1339. Each MGO-component was administered at a dose identical to that contained in the 4% dose of MGO. Twenty-four h later, blood was collected from the hearts of animals in heparinized tubes, and plasma samples were prepared and assayed for total cholesterol, LDL-cholesterol, and triglycerides. The percent change caused by the various MGO components (C) is expressed relative to the group of Triton WR-1339-treated rats (B), which was taken as 100%. The values represent mean ± SD of six rats. Values of camphene treated rats were significantly different as compared to Triton WR-1339 treated rats with ppp>0.05).